Europe Cell and Gene Therapy Market - Industry Outlook and Forecast 2021-2026
In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Europe Cell and Gene Therapy Market Report
The Europe cell and gene therapy market by revenue is expected to grow at a CAGR of over 23% during the period 2021–2026.
The global cell and gene therapy market is observing significant mergers and acquisition activities, product sales, and new market authorizations. In 2026, the market is expected to grow almost four times more than the current value, with new product approvals expected annually. Although initial product approvals have been for relatively small patient groups, the significant pipeline of cell & gene therapy studies for diseases such as hemophilia and various forms of blindness will significantly expand. In addition, the Europe market is witnessing steady growth due to the increased availability of funds from several public and private institutes. There is increased support from regulatory bodies for product approvals and fast-track product designations, which encourage vendors to manufacture products at a fast rate. Moreover, with over 237 regenerative medicines companies headquartered in Europe, the region is seen as the favorite destination for cell and gene therapy manufacturing.
The following factors are likely to contribute to the growth of the Europe cell and gene therapy market during the forecast period:
Europe Cell and Gene Therapy Market Segmentation
The Europe cell and gene therapy market research report includes a detailed segmentation by product, end-user, application, geography. A high potential to treat several chronic diseases, which cannot be effectively treated/cured through conventional methods otherwise, is propelling the growth of gene therapies. Gene therapies are regarded as a potential revolution in the health sciences and pharmaceutical fields. The number of clinical trials investigating gene therapies is increasing in Europe, despite the limited number of products that have successfully reached the market. However, gene therapies show slow progress and promising prospect in terms of treatments. High support from regulatory bodies to commercialize these products and make them affordable to patients is another important factor contributing the market growth.
Delivering cell and gene therapies requires specialized facilities, capabilities, and clinician skills. Therefore, manufacturers are working in tandem with chosen treatment centers (hospitals) to establish the protocols and procedures necessary to receive the product and therapies. While cell therapies represent a paradigm shift in the treatment of several incurable, chronic diseases, with durable responses and long-term disease control measures, hospitals appear an ideal location to carry out these procedures. Hospitals are growing at a significant rate due to the increasing target population in Europe. Tier-I hospitals are proving to be sought-after network partners for cell and gene therapy developers. They tend to be in major population centers, have adequate financial and personnel resources, and value the prestige that comes with being the first movers in an innovative treatment area.
Oncology accounted for a share of over 30% in 2020. While cancer treatments have evolved and undergone massive developments in recent years, it continues to be one of the deadliest diseases confronted by humans. Traditional cancer therapies have a curative effect in the short term; however, they have side effects, thereby decreasing the patient’s quality of life. Cell and gene therapies for certain types of cancers have been promising results. The chimeric antigen receptor- (CAR-) T cell therapy is one of the most recent innovative immunotherapies and is rapidly evolving. CAR-T cell therapies are developing rapidly, and many clinical trials have been established on a global scale, which has high commercial potential for the treatment of cancer. Immunotherapies based on CAR-T cells go one step further, engineering the T cells themselves to enhance the natural immune response against a specific tumor antigen. CAR-T clinical trials have shown high remission rates, up to 94%, in severe forms of blood cancer, thereby increasing the market growth.
Product
Germany, France, the UK, Italy, and Spain play a significant role in the Europe cell and gene therapy market. Clinical trials and the number of manufacturing facilities are increasing slowly in the European region. The region has become a major R&D destination for several vendors as the funding for cell & gene therapies is increasing. Europe has supported collaborative efforts in gene transfer and gene therapy research. In addition, the target patient population is increasing across Europe; there were an estimated 3.9 million new cases of cancer and 1.9 million cancer deaths in Europe in 2018. In addition, the prevalence surveys in the UK and Denmark indicate that there are 3–4 people with one or more wounds per 1,000 people. Favorable government support in terms of product approvals, reimbursement and coverage, and high R&D funding to academic institutes that are involved in the development of cell and gene therapies are expected to boosting the market in Europe.
Geography
Novartis, Spark Therapeutics, Amgen, Gilead Sciences, and Organogenesis are the leading players in the Europe cell and gene therapy market. The market offers tremendous growth opportunities for existing and future/emerging players on account of the presence of a large pool of target patient population with chronic diseases such as cancer, wound disorders, diabetic foot ulcer, CVDs, and other genetic disorders. Recent approvals have prompted an unprecedented expansion among vendors. While a few vendors are opting for in-house production of cell and gene therapies, a substantial number of vendors are preferring third-party service providers, including CMOs.
Prominent Vendors
1. What is the Europe cell and gene therapy market size and growth rate during the forecast period?
2. What are the factors driving the demand for CAR-T therapy in the European region?
3. How are strategic acquisitions aiding in market growth of cell and gene therapy products?
4. Which segments are expected to generate the highest revenues during the forecast period?
5. Who are the leading vendors in the European cell and gene therapy market?
The Europe cell and gene therapy market by revenue is expected to grow at a CAGR of over 23% during the period 2021–2026.
The global cell and gene therapy market is observing significant mergers and acquisition activities, product sales, and new market authorizations. In 2026, the market is expected to grow almost four times more than the current value, with new product approvals expected annually. Although initial product approvals have been for relatively small patient groups, the significant pipeline of cell & gene therapy studies for diseases such as hemophilia and various forms of blindness will significantly expand. In addition, the Europe market is witnessing steady growth due to the increased availability of funds from several public and private institutes. There is increased support from regulatory bodies for product approvals and fast-track product designations, which encourage vendors to manufacture products at a fast rate. Moreover, with over 237 regenerative medicines companies headquartered in Europe, the region is seen as the favorite destination for cell and gene therapy manufacturing.
The following factors are likely to contribute to the growth of the Europe cell and gene therapy market during the forecast period:
- CMOs Offering Vector Manufacturing Services for Cell and Gene Therapy Companies
- Robust Cell & Gene Therapies in the Pipeline
- Increase in Strategic Acquisitions
- Regulatory Support for Cell and Gene Therapy Products
Europe Cell and Gene Therapy Market Segmentation
The Europe cell and gene therapy market research report includes a detailed segmentation by product, end-user, application, geography. A high potential to treat several chronic diseases, which cannot be effectively treated/cured through conventional methods otherwise, is propelling the growth of gene therapies. Gene therapies are regarded as a potential revolution in the health sciences and pharmaceutical fields. The number of clinical trials investigating gene therapies is increasing in Europe, despite the limited number of products that have successfully reached the market. However, gene therapies show slow progress and promising prospect in terms of treatments. High support from regulatory bodies to commercialize these products and make them affordable to patients is another important factor contributing the market growth.
Delivering cell and gene therapies requires specialized facilities, capabilities, and clinician skills. Therefore, manufacturers are working in tandem with chosen treatment centers (hospitals) to establish the protocols and procedures necessary to receive the product and therapies. While cell therapies represent a paradigm shift in the treatment of several incurable, chronic diseases, with durable responses and long-term disease control measures, hospitals appear an ideal location to carry out these procedures. Hospitals are growing at a significant rate due to the increasing target population in Europe. Tier-I hospitals are proving to be sought-after network partners for cell and gene therapy developers. They tend to be in major population centers, have adequate financial and personnel resources, and value the prestige that comes with being the first movers in an innovative treatment area.
Oncology accounted for a share of over 30% in 2020. While cancer treatments have evolved and undergone massive developments in recent years, it continues to be one of the deadliest diseases confronted by humans. Traditional cancer therapies have a curative effect in the short term; however, they have side effects, thereby decreasing the patient’s quality of life. Cell and gene therapies for certain types of cancers have been promising results. The chimeric antigen receptor- (CAR-) T cell therapy is one of the most recent innovative immunotherapies and is rapidly evolving. CAR-T cell therapies are developing rapidly, and many clinical trials have been established on a global scale, which has high commercial potential for the treatment of cancer. Immunotherapies based on CAR-T cells go one step further, engineering the T cells themselves to enhance the natural immune response against a specific tumor antigen. CAR-T clinical trials have shown high remission rates, up to 94%, in severe forms of blood cancer, thereby increasing the market growth.
Product
- Cell Therapies
- Gene Therapies
- Hospitals
- Cancer Care Centers
- Wound Care Centers
- Others
- Oncology
- Dermatology
- Musculoskeletal
- Others
Germany, France, the UK, Italy, and Spain play a significant role in the Europe cell and gene therapy market. Clinical trials and the number of manufacturing facilities are increasing slowly in the European region. The region has become a major R&D destination for several vendors as the funding for cell & gene therapies is increasing. Europe has supported collaborative efforts in gene transfer and gene therapy research. In addition, the target patient population is increasing across Europe; there were an estimated 3.9 million new cases of cancer and 1.9 million cancer deaths in Europe in 2018. In addition, the prevalence surveys in the UK and Denmark indicate that there are 3–4 people with one or more wounds per 1,000 people. Favorable government support in terms of product approvals, reimbursement and coverage, and high R&D funding to academic institutes that are involved in the development of cell and gene therapies are expected to boosting the market in Europe.
Geography
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Switzerland
- Netherlands
Novartis, Spark Therapeutics, Amgen, Gilead Sciences, and Organogenesis are the leading players in the Europe cell and gene therapy market. The market offers tremendous growth opportunities for existing and future/emerging players on account of the presence of a large pool of target patient population with chronic diseases such as cancer, wound disorders, diabetic foot ulcer, CVDs, and other genetic disorders. Recent approvals have prompted an unprecedented expansion among vendors. While a few vendors are opting for in-house production of cell and gene therapies, a substantial number of vendors are preferring third-party service providers, including CMOs.
Prominent Vendors
- Novartis
- Spark Therapeutics
- Amgen
- Gilead Sciences
- Organogenesis
- APAC Biotech
- AVITA Medical
- bluebird bio
- CHIESI Farmaceutici
- CollPlant
- CO.DON
- Human Stem Cells Institute PJSC (HSCI)
- Medipost
- NuVasive
- Nipro
- Orchard Therapeutics
- RMS Regenerative Medical System
- Orthocell
- Osiris Therapeutics
- Sibino GeneTech
- Shanghai Sunway Biotech
- Takeda Pharmaceutical Company
- Terumo
- Vericel
- Adaptimmune Therapeutics
- AgenTus Therapeutics
- Autolus
- Cellecits
- Celyad
- CombiGene
- EUKAR?S
- Freeline Therapeutics
- Innoskel
- PsiOxus Therapeutics Ltd
- SparingVision
- uniQure
1. What is the Europe cell and gene therapy market size and growth rate during the forecast period?
2. What are the factors driving the demand for CAR-T therapy in the European region?
3. How are strategic acquisitions aiding in market growth of cell and gene therapy products?
4. Which segments are expected to generate the highest revenues during the forecast period?
5. Who are the leading vendors in the European cell and gene therapy market?
1 RESEARCH METHODOLOGY
2 RESEARCH OBJECTIVES
3 RESEARCH PROCESS
4 SCOPE & COVERAGE
4.1 Market Definition
4.1.1 Inclusions
4.1.2 Exclusions
4.2 Base Year
4.3 Scope of The Study
4.3.1 Market Segmentation by Product
4.3.2 Market Segmentation by Application
4.3.3 Market Segmentation by End-Users
4.3.4 Market Segmentation by Geography
5 REPORT ASSUMPTIONS & CAVEATS
5.1 Key Caveats
5.2 Currency Conversion
5.3 Market Derivation
6 MARKET AT A GLANCE
7 INTRODUCTION
7.1 Overview
8 MARKET OPPORTUNITIES & TRENDS
8.1 CMO Offering Vector-Manufacturing Services
8.2 Robust Cell & Gene Therapy Pipeline
8.3 Increase In Strategic Acquisitions
9 MARKET GROWTH ENABLERS
9.1 Regulatory Support For Cell And Gene Therapy Market
9.2 Increasing Demand For CAR-T Therapy In Europe
9.3 Product Launches And Approvals
10 MARKET RESTRAINTS
10.1 COVID-19 Impact on Cell And Gene Therapy Products
10.2 Increasing Pricing Pressure for Cell & Gene Therapy Products
10.3 Limitations of Gene Therapy Products
11 MARKET LANDSCAPE
11.1 Market Overview
11.2 Market Size & Forecast
11.3 Five Forces Analysis
11.3.1 Threat of New Entrants
11.3.2 Bargaining Power of Suppliers
11.3.3 Bargaining Power of Buyers
11.3.4 Threat of Substitutes
11.3.5 Competitive Rivalry
12 PRODUCT
12.1 Market Snapshot & Growth Engine
12.2 Market Overview
12.3 Cell Therapy
12.3.1 Market Overview
12.3.2 Market Size & Forecast
12.4 Gene Therapy
12.4.1 Market Overview
12.4.2 Market Size & Forecast
13 APPLICATION
13.1 Market Snapshot & Growth Engine
13.2 Market Overview
13.3 Oncology
13.3.1 Market Overview
13.3.2 Market Size & Forecast
13.4 Dermatology
13.4.1 Market Overview
13.4.2 Market Size & Forecast
13.5 Musculoskeletal
13.5.1 Market Overview
13.5.2 Market Size & Forecast
13.6 Others
13.6.1 Market Overview
13.6.2 Market Size & Forecast
14 END-USERS
14.1 Market Snapshot & Growth Engine
14.2 Market Overview
14.3 Hospitals
14.3.1 Market Overview
14.3.2 Market Size & Forecast
14.4 Cancer Care Centers
14.4.1 Market Overview
14.4.2 Market Size & Forecast
14.5 Wound Care Centers
14.5.1 Market Overview
14.5.2 Market Size & Forecast
14.6 Others
14.6.1 Market Overview
14.6.2 Market Size & Forecast
15 GEOGRAPHY
15.1 Market Snapshot & Growth Engine
15.2 Geographic Overview
16 WESTERN EUROPE
16.1 Market Overview
16.2 Market Size & Forecast
17 REST OF EUROPE
17.1 Market Overview
17.2 Market Size & Forecast
18 KEY COUNTRIES
18.1 Germany: Market Size & Forecast
18.2 France: Market Size & Forecast
18.3 UK: Market Size & Forecast
18.4 Italy: Market Size & Forecast
18.5 Spain: Market Size & Forecast
18.6 Switzerland: Market Size & Forecast
18.7 The Netherlands: Market Size & Forecast
19 COMPETITIVE LANDSCAPE
19.1 Competition Overview
19.2 Market Share Analysis
19.2.1 Novartis
19.2.2 Spark Therapeutics
19.2.3 Amgen
19.2.4 Gilead Sciences
19.2.5 Organogenesis
20 KEY COMPANY PROFILES
20.1 Novartis
20.1.1 Business Overview
20.1.2 Product Offerings
20.1.3 Key Strategies
20.1.4 Key Strengths
20.1.5 Key Opportunities
20.2 Spark Therapeutics
20.2.1 Business Overview
20.2.2 Product Offerings
20.2.3 Key Strategies
20.2.4 Key Strengths
20.2.5 Key Opportunities
20.3 AMGEN
20.3.1 Business Overview
20.3.2 Product Offerings
20.3.3 Key Strategies
20.3.4 Key Strengths
20.3.5 Key Opportunities
20.4 Gilead Sciences
20.4.1 Business Overview
20.4.2 Product Offerings
20.4.3 Key Strategies
20.4.4 Key Strengths
20.4.5 Key Opportunities
20.5 Organogenesis
20.5.1 Business Overview
20.5.2 Product Offerings
20.5.3 Key Strategies
20.5.4 Key Strengths
20.5.5 Key Opportunities
21 OTHER PROMINENT VENDORS
21.1 APAC Biotech
21.1.1 Business Overview
21.1.2 Product Offerings
21.2 Avita Medical
21.2.1 Business Overview
21.2.2 Product Offerings
21.3 bluebird bio
21.3.1 Business Overview
21.3.2 Product Offerings
21.4 Chiesi Farmaceutici
21.4.1 Business Overview
21.4.2 Product Offerings
21.5 Collplant
21.5.1 Business Overview
21.5.2 Product Offerings
21.6 CO.DON
21.6.1 Business Overview
21.6.2 Product Offerings
21.7 Human Stem Cell Institute
21.7.1 Business Overview
21.7.2 Product Offerings
21.8 Medipost
21.8.1 Business Overview
21.8.2 Product Offerings
21.9 Nuvasive
21.9.1 Business Overview
21.9.2 Product Offerings
21.10 Nipro
21.10.1 Business Overview
21.10.2 Product Offerings
21.11 Orchard Therapeutics
21.11.1 Business Overview
21.11.2 Product Offerings
21.12 RMS Regenerative Medical System
21.12.1 Business Overview
21.12.2 Product Offerings
21.13 Orthocell
21.13.1 Business Overview
21.13.2 Product Offerings
21.14 Osiris Therapeutics
21.14.1 Business Overview
21.14.2 Product Offerings
21.15 Sibiono Genetech
21.15.1 Business Overview
21.15.2 Product Offerings
21.16 Shanghai Sunway Biotech
21.16.1 Business Overview
21.16.2 Product Offerings
21.17 Takeda Pharmaceutical Company
21.17.1 Business Overview
21.17.2 Product Offerings
21.18 Terumo
21.18.1 Business Overview
21.18.2 Product Offerings
21.19 Vericel
21.19.1 Business Overview
21.19.2 Product Offerings
22 EMERGING INVESTIGATIONAL VENDORS IN EUROPE
22.1 Adaptimmune Therapeutics
22.1.1 Business Overview
22.2 AgenTus
22.2.1 Business Overview
22.3 Autolus
22.3.1 Business Overview
22.4 Cellecits
22.4.1 Business Overview
22.5 Celyad
22.5.1 Business Overview
22.6 CombiGene
22.6.1 Business Overview
22.7 EUKAR?S
22.7.1 Business Overview
22.8 Freeline Therapeutics
22.8.1 Business Overview
22.9 Innoskel
22.9.1 Business Overview
22.10 PSIOXUS Therapeutics
22.10.1 Business Overview
22.11 Sparing Vision
22.11.1 Business Overview
22.12 Uniqure
22.12.1 Business Overview
23 REPORT SUMMARY
23.1 Key Takeaways
23.2 Strategic Recommendations
24 QUANTITATIVE SUMMARY
24.1 Market by Geography
24.2 Market by Product
24.3 Market by End-User
24.4 Market by Application
25 APPENDIX
25.1 Abbreviations
2 RESEARCH OBJECTIVES
3 RESEARCH PROCESS
4 SCOPE & COVERAGE
4.1 Market Definition
4.1.1 Inclusions
4.1.2 Exclusions
4.2 Base Year
4.3 Scope of The Study
4.3.1 Market Segmentation by Product
4.3.2 Market Segmentation by Application
4.3.3 Market Segmentation by End-Users
4.3.4 Market Segmentation by Geography
5 REPORT ASSUMPTIONS & CAVEATS
5.1 Key Caveats
5.2 Currency Conversion
5.3 Market Derivation
6 MARKET AT A GLANCE
7 INTRODUCTION
7.1 Overview
8 MARKET OPPORTUNITIES & TRENDS
8.1 CMO Offering Vector-Manufacturing Services
8.2 Robust Cell & Gene Therapy Pipeline
8.3 Increase In Strategic Acquisitions
9 MARKET GROWTH ENABLERS
9.1 Regulatory Support For Cell And Gene Therapy Market
9.2 Increasing Demand For CAR-T Therapy In Europe
9.3 Product Launches And Approvals
10 MARKET RESTRAINTS
10.1 COVID-19 Impact on Cell And Gene Therapy Products
10.2 Increasing Pricing Pressure for Cell & Gene Therapy Products
10.3 Limitations of Gene Therapy Products
11 MARKET LANDSCAPE
11.1 Market Overview
11.2 Market Size & Forecast
11.3 Five Forces Analysis
11.3.1 Threat of New Entrants
11.3.2 Bargaining Power of Suppliers
11.3.3 Bargaining Power of Buyers
11.3.4 Threat of Substitutes
11.3.5 Competitive Rivalry
12 PRODUCT
12.1 Market Snapshot & Growth Engine
12.2 Market Overview
12.3 Cell Therapy
12.3.1 Market Overview
12.3.2 Market Size & Forecast
12.4 Gene Therapy
12.4.1 Market Overview
12.4.2 Market Size & Forecast
13 APPLICATION
13.1 Market Snapshot & Growth Engine
13.2 Market Overview
13.3 Oncology
13.3.1 Market Overview
13.3.2 Market Size & Forecast
13.4 Dermatology
13.4.1 Market Overview
13.4.2 Market Size & Forecast
13.5 Musculoskeletal
13.5.1 Market Overview
13.5.2 Market Size & Forecast
13.6 Others
13.6.1 Market Overview
13.6.2 Market Size & Forecast
14 END-USERS
14.1 Market Snapshot & Growth Engine
14.2 Market Overview
14.3 Hospitals
14.3.1 Market Overview
14.3.2 Market Size & Forecast
14.4 Cancer Care Centers
14.4.1 Market Overview
14.4.2 Market Size & Forecast
14.5 Wound Care Centers
14.5.1 Market Overview
14.5.2 Market Size & Forecast
14.6 Others
14.6.1 Market Overview
14.6.2 Market Size & Forecast
15 GEOGRAPHY
15.1 Market Snapshot & Growth Engine
15.2 Geographic Overview
16 WESTERN EUROPE
16.1 Market Overview
16.2 Market Size & Forecast
17 REST OF EUROPE
17.1 Market Overview
17.2 Market Size & Forecast
18 KEY COUNTRIES
18.1 Germany: Market Size & Forecast
18.2 France: Market Size & Forecast
18.3 UK: Market Size & Forecast
18.4 Italy: Market Size & Forecast
18.5 Spain: Market Size & Forecast
18.6 Switzerland: Market Size & Forecast
18.7 The Netherlands: Market Size & Forecast
19 COMPETITIVE LANDSCAPE
19.1 Competition Overview
19.2 Market Share Analysis
19.2.1 Novartis
19.2.2 Spark Therapeutics
19.2.3 Amgen
19.2.4 Gilead Sciences
19.2.5 Organogenesis
20 KEY COMPANY PROFILES
20.1 Novartis
20.1.1 Business Overview
20.1.2 Product Offerings
20.1.3 Key Strategies
20.1.4 Key Strengths
20.1.5 Key Opportunities
20.2 Spark Therapeutics
20.2.1 Business Overview
20.2.2 Product Offerings
20.2.3 Key Strategies
20.2.4 Key Strengths
20.2.5 Key Opportunities
20.3 AMGEN
20.3.1 Business Overview
20.3.2 Product Offerings
20.3.3 Key Strategies
20.3.4 Key Strengths
20.3.5 Key Opportunities
20.4 Gilead Sciences
20.4.1 Business Overview
20.4.2 Product Offerings
20.4.3 Key Strategies
20.4.4 Key Strengths
20.4.5 Key Opportunities
20.5 Organogenesis
20.5.1 Business Overview
20.5.2 Product Offerings
20.5.3 Key Strategies
20.5.4 Key Strengths
20.5.5 Key Opportunities
21 OTHER PROMINENT VENDORS
21.1 APAC Biotech
21.1.1 Business Overview
21.1.2 Product Offerings
21.2 Avita Medical
21.2.1 Business Overview
21.2.2 Product Offerings
21.3 bluebird bio
21.3.1 Business Overview
21.3.2 Product Offerings
21.4 Chiesi Farmaceutici
21.4.1 Business Overview
21.4.2 Product Offerings
21.5 Collplant
21.5.1 Business Overview
21.5.2 Product Offerings
21.6 CO.DON
21.6.1 Business Overview
21.6.2 Product Offerings
21.7 Human Stem Cell Institute
21.7.1 Business Overview
21.7.2 Product Offerings
21.8 Medipost
21.8.1 Business Overview
21.8.2 Product Offerings
21.9 Nuvasive
21.9.1 Business Overview
21.9.2 Product Offerings
21.10 Nipro
21.10.1 Business Overview
21.10.2 Product Offerings
21.11 Orchard Therapeutics
21.11.1 Business Overview
21.11.2 Product Offerings
21.12 RMS Regenerative Medical System
21.12.1 Business Overview
21.12.2 Product Offerings
21.13 Orthocell
21.13.1 Business Overview
21.13.2 Product Offerings
21.14 Osiris Therapeutics
21.14.1 Business Overview
21.14.2 Product Offerings
21.15 Sibiono Genetech
21.15.1 Business Overview
21.15.2 Product Offerings
21.16 Shanghai Sunway Biotech
21.16.1 Business Overview
21.16.2 Product Offerings
21.17 Takeda Pharmaceutical Company
21.17.1 Business Overview
21.17.2 Product Offerings
21.18 Terumo
21.18.1 Business Overview
21.18.2 Product Offerings
21.19 Vericel
21.19.1 Business Overview
21.19.2 Product Offerings
22 EMERGING INVESTIGATIONAL VENDORS IN EUROPE
22.1 Adaptimmune Therapeutics
22.1.1 Business Overview
22.2 AgenTus
22.2.1 Business Overview
22.3 Autolus
22.3.1 Business Overview
22.4 Cellecits
22.4.1 Business Overview
22.5 Celyad
22.5.1 Business Overview
22.6 CombiGene
22.6.1 Business Overview
22.7 EUKAR?S
22.7.1 Business Overview
22.8 Freeline Therapeutics
22.8.1 Business Overview
22.9 Innoskel
22.9.1 Business Overview
22.10 PSIOXUS Therapeutics
22.10.1 Business Overview
22.11 Sparing Vision
22.11.1 Business Overview
22.12 Uniqure
22.12.1 Business Overview
23 REPORT SUMMARY
23.1 Key Takeaways
23.2 Strategic Recommendations
24 QUANTITATIVE SUMMARY
24.1 Market by Geography
24.2 Market by Product
24.3 Market by End-User
24.4 Market by Application
25 APPENDIX
25.1 Abbreviations
LIST OF EXHIBITS
Exhibit 1 Cell and Gene Therapy Market in Europe: Segmentation
Exhibit 2 Market Size Calculation Approach 2020
Exhibit 3 ATMPs in Development in Europe 2019
Exhibit 4 Impact of CMOs Offering Vector-Manufacturing Services
Exhibit 5 Cell & Gene Therapy Supply Chain
Exhibit 6 Impact of Robust Cell & Gene Therapy Pipeline
Exhibit 7 Impact of Increase in Strategic Acquisitions
Exhibit 8 Impact of Regulatory Support for Cell and Gene Therapy Market
Exhibit 9 Regulatory Pathway for Market Approval in Europe
Exhibit 10 Impact of Increasing Demand for CAR-T Therapy in Europe
Exhibit 11 Impact of Product Launches and Approvals
Exhibit 12 Impact of Covid-19 on Cell and Gene Therapy Products
Exhibit 13 Gene Therapy Trials Disrupted by Covid-19
Exhibit 14 Impact of Increasing Pricing Pressure for the Cell and Gene Therapy Products
Exhibit 15 Impact of Limitations of Gene Therapy Products
Exhibit 16 Cell & Gene Therapy Expenditure by European Companies 2019 ($ billion)
Exhibit 17 Recent Development & Commercialization of Cell &Gene Therapy Products in Europe
Exhibit 18 Cell & Gene Therapy Market in Europe by Product 2020 & 2026 (% share)
Exhibit 19 Cell & Gene Therapy Market in Europe by Application 2020 & 2026 (% share)
Exhibit 20 Cell & Gene Therapy Market in Europe by End-Users 2020 & 2026 Percentage Share Comparison
Exhibit 21 Cell & Gene Therapy Market in Europe by Geography: 2020 & 2026 (% share)
Exhibit 22 Cell & Gene Therapy Market in Europe 2020–2026 ($ million)
Exhibit 23 Five Forces Analysis 2020
Exhibit 24 Incremental Growth by Product 2020 & 2026
Exhibit 25 Europe Cell & Gene Therapy Market Segmentation by Product
Exhibit 26 Europe Cell & Gene Therapy Market by Product: Incremental Growth
Exhibit 27 Europe Cell & Gene Therapy Market by Product: Absolute Growth
Exhibit 28 CAR-T Cell Treated Patients Registered in EMBT Registry
Exhibit 29 Cell & Gene Therapy Market by Cell Therapy in Europe: Incremental Growth & Absolute Growth Comparison
Exhibit 30 Cell & Gene Therapy Market in Europe by Cell Therapy Product 2020–2026 ($ million)
Exhibit 31 Cell & Gene Therapy Market in Europe by Gene Therapy: Incremental Growth & Absolute Growth Comparison
Exhibit 32 Cell & Gene Therapy Market in Europe by Gene Therapy Product 2020–2026 ($ million)
Exhibit 33 Incremental Growth by Application 2020 & 2026
Exhibit 34 Europe Cell & Gene Therapy Market Segmentation by Application
Exhibit 35 Cell & Gene Therapy Market in Europe by Application: Incremental Growth
Exhibit 36 Europe Cell & Gene Therapy Market by Application: Absolute Growth
Exhibit 37 Europe Cell & Gene Therapy Market by Oncology: Incremental Growth & Absolute Growth Comparison
Exhibit 38 Europe Cell & Gene Therapy Market by Oncology 2020–2026 ($ million)
Exhibit 39 Europe Cell & Gene Therapy Market by Dermatology: Incremental Growth & Absolute Growth Comparison
Exhibit 40 Cell & Gene Therapy Market in Europe by Dermatology 2020–2026 ($ million)
Exhibit 41 Europe Cell & Gene Therapy Market by Musculoskeletal: Incremental Growth & Absolute Growth Comparison
Exhibit 42 Cell & Gene Therapy Market in Europe by Musculoskeletal 2020–2026 ($ million)
Exhibit 43 Cell & Gene Therapy Market in Europe by Others: Incremental Growth & Absolute Growth Comparison
Exhibit 44 Cell & Gene Therapy Market in Europe by Others 2020–2026 ($ million)
Exhibit 45 Incremental Growth by End-Users 2020 & 2026
Exhibit 46 Europe Cell & Gene Therapy Market Segmentation by End-user
Exhibit 47 Cell & Gene Therapy Market in Europe by End-User: Incremental Growth
Exhibit 48 Cell & Gene Therapy Market in Europe by End-User: Absolute Growth
Exhibit 49 Cell & Gene Therapy Market in Europe by Hospitals: Incremental Growth & Absolute Growth Comparison
Exhibit 50 Cell & Gene Therapy Market in Europe by Hospitals 2020–2026 ($ million)
Exhibit 51 Cell & Gene Therapy Market in Europe by Cancer Care Centers: Incremental Growth & Absolute Growth Comparison
Exhibit 52 Cell & Gene Therapy Market by Cancer Care Centers in Europe 2020–2026 ($ million)
Exhibit 53 Cell & Gene Therapy Market in Europe by Wound Care Centers: Incremental Growth & Absolute Growth Comparison
Exhibit 54 Cell & Gene Therapy Market by Wound Care Clinics in Europe 2020–2026 ($ million)
Exhibit 55 Cell & Gene Therapy Market in Europe by Others: Incremental Growth & Absolute Growth Comparison
Exhibit 56 Cell & Gene Therapy Market in Europe by Others 2020–2026 ($ million)
Exhibit 57 Incremental Growth by Geography 2020 & 2026
Exhibit 58 Europe Cell & Gene Therapy Market Segmentation by Geography
Exhibit 59 Cell & Gene Therapy Market in Europe by Geography: Incremental Growth
Exhibit 60 Cell & Gene Therapy Market in Europe by Geography: Absolute Growth
Exhibit 61 Global Audience of European Society of Cell & Gene Therapy
Exhibit 62 Main Contribution for European Society of Cell and Gene Therapy
Exhibit 63 Healthcare Expenditure of Western European Countries Relative to their GDP
Exhibit 64 Cell & Gene Therapy Market in Western Europe: Incremental Growth & Absolute Growth Comparison
Exhibit 65 Cell & Gene Therapy Market in Western Europe 2020–2026 ($ million)
Exhibit 66 Healthcare Expenditure of Eastern European Countries Relative to their GDP
Exhibit 67 Cell & Gene Therapy Market in Rest of Europe: Incremental Growth & Absolute Growth Comparison
Exhibit 68 Cell & Gene Therapy Market in Rest of Europe 2020–2026 ($ million)
Exhibit 69 Incremental Growth in Key Countries 2020 & 2026
Exhibit 70 Cell and Gene Therapy Market in Germany 2020–2026 ($ million)
Exhibit 71 Cell and Gene Therapy Market in France 2020–2026 ($ million)
Exhibit 72 Cell and Gene Therapy Market in UK 2020–2026 ($ million)
Exhibit 73 Cell and Gene Therapy Market in Italy 2020–2026 ($ million)
Exhibit 74 Cell and Gene Therapy Market in Spain 2020–2026 ($ million)
Exhibit 75 Cell and Gene Therapy Market in Switzerland 2020–2026 ($ million)
Exhibit 76 Cell and Gene Therapy Market in Netherlands 2020–2026 ($ million)
Exhibit 77 Novartis Revenue 2017-2019 ($ billion)
Exhibit 78 Novartis Segment Revenue Share 2019
Exhibit 79 Novartis: Regional Revenue Breakup 2019 (%)
Exhibit 80 Amgen Revenue 2019 - 2017 ($ billion)
Exhibit 81 Amgen: R&D Expenditure 2019 - 2017 ($ billion)
Exhibit 82 Gilead Sciences Revenue 2017–2019 ($ billion)
Exhibit 83 Gilead Sciences Research &Development Expenses 2017–2019 ($ billion)
Exhibit 84 Organogenesis Revenue 2018–2019 ($ million)
Exhibit 1 Cell and Gene Therapy Market in Europe: Segmentation
Exhibit 2 Market Size Calculation Approach 2020
Exhibit 3 ATMPs in Development in Europe 2019
Exhibit 4 Impact of CMOs Offering Vector-Manufacturing Services
Exhibit 5 Cell & Gene Therapy Supply Chain
Exhibit 6 Impact of Robust Cell & Gene Therapy Pipeline
Exhibit 7 Impact of Increase in Strategic Acquisitions
Exhibit 8 Impact of Regulatory Support for Cell and Gene Therapy Market
Exhibit 9 Regulatory Pathway for Market Approval in Europe
Exhibit 10 Impact of Increasing Demand for CAR-T Therapy in Europe
Exhibit 11 Impact of Product Launches and Approvals
Exhibit 12 Impact of Covid-19 on Cell and Gene Therapy Products
Exhibit 13 Gene Therapy Trials Disrupted by Covid-19
Exhibit 14 Impact of Increasing Pricing Pressure for the Cell and Gene Therapy Products
Exhibit 15 Impact of Limitations of Gene Therapy Products
Exhibit 16 Cell & Gene Therapy Expenditure by European Companies 2019 ($ billion)
Exhibit 17 Recent Development & Commercialization of Cell &Gene Therapy Products in Europe
Exhibit 18 Cell & Gene Therapy Market in Europe by Product 2020 & 2026 (% share)
Exhibit 19 Cell & Gene Therapy Market in Europe by Application 2020 & 2026 (% share)
Exhibit 20 Cell & Gene Therapy Market in Europe by End-Users 2020 & 2026 Percentage Share Comparison
Exhibit 21 Cell & Gene Therapy Market in Europe by Geography: 2020 & 2026 (% share)
Exhibit 22 Cell & Gene Therapy Market in Europe 2020–2026 ($ million)
Exhibit 23 Five Forces Analysis 2020
Exhibit 24 Incremental Growth by Product 2020 & 2026
Exhibit 25 Europe Cell & Gene Therapy Market Segmentation by Product
Exhibit 26 Europe Cell & Gene Therapy Market by Product: Incremental Growth
Exhibit 27 Europe Cell & Gene Therapy Market by Product: Absolute Growth
Exhibit 28 CAR-T Cell Treated Patients Registered in EMBT Registry
Exhibit 29 Cell & Gene Therapy Market by Cell Therapy in Europe: Incremental Growth & Absolute Growth Comparison
Exhibit 30 Cell & Gene Therapy Market in Europe by Cell Therapy Product 2020–2026 ($ million)
Exhibit 31 Cell & Gene Therapy Market in Europe by Gene Therapy: Incremental Growth & Absolute Growth Comparison
Exhibit 32 Cell & Gene Therapy Market in Europe by Gene Therapy Product 2020–2026 ($ million)
Exhibit 33 Incremental Growth by Application 2020 & 2026
Exhibit 34 Europe Cell & Gene Therapy Market Segmentation by Application
Exhibit 35 Cell & Gene Therapy Market in Europe by Application: Incremental Growth
Exhibit 36 Europe Cell & Gene Therapy Market by Application: Absolute Growth
Exhibit 37 Europe Cell & Gene Therapy Market by Oncology: Incremental Growth & Absolute Growth Comparison
Exhibit 38 Europe Cell & Gene Therapy Market by Oncology 2020–2026 ($ million)
Exhibit 39 Europe Cell & Gene Therapy Market by Dermatology: Incremental Growth & Absolute Growth Comparison
Exhibit 40 Cell & Gene Therapy Market in Europe by Dermatology 2020–2026 ($ million)
Exhibit 41 Europe Cell & Gene Therapy Market by Musculoskeletal: Incremental Growth & Absolute Growth Comparison
Exhibit 42 Cell & Gene Therapy Market in Europe by Musculoskeletal 2020–2026 ($ million)
Exhibit 43 Cell & Gene Therapy Market in Europe by Others: Incremental Growth & Absolute Growth Comparison
Exhibit 44 Cell & Gene Therapy Market in Europe by Others 2020–2026 ($ million)
Exhibit 45 Incremental Growth by End-Users 2020 & 2026
Exhibit 46 Europe Cell & Gene Therapy Market Segmentation by End-user
Exhibit 47 Cell & Gene Therapy Market in Europe by End-User: Incremental Growth
Exhibit 48 Cell & Gene Therapy Market in Europe by End-User: Absolute Growth
Exhibit 49 Cell & Gene Therapy Market in Europe by Hospitals: Incremental Growth & Absolute Growth Comparison
Exhibit 50 Cell & Gene Therapy Market in Europe by Hospitals 2020–2026 ($ million)
Exhibit 51 Cell & Gene Therapy Market in Europe by Cancer Care Centers: Incremental Growth & Absolute Growth Comparison
Exhibit 52 Cell & Gene Therapy Market by Cancer Care Centers in Europe 2020–2026 ($ million)
Exhibit 53 Cell & Gene Therapy Market in Europe by Wound Care Centers: Incremental Growth & Absolute Growth Comparison
Exhibit 54 Cell & Gene Therapy Market by Wound Care Clinics in Europe 2020–2026 ($ million)
Exhibit 55 Cell & Gene Therapy Market in Europe by Others: Incremental Growth & Absolute Growth Comparison
Exhibit 56 Cell & Gene Therapy Market in Europe by Others 2020–2026 ($ million)
Exhibit 57 Incremental Growth by Geography 2020 & 2026
Exhibit 58 Europe Cell & Gene Therapy Market Segmentation by Geography
Exhibit 59 Cell & Gene Therapy Market in Europe by Geography: Incremental Growth
Exhibit 60 Cell & Gene Therapy Market in Europe by Geography: Absolute Growth
Exhibit 61 Global Audience of European Society of Cell & Gene Therapy
Exhibit 62 Main Contribution for European Society of Cell and Gene Therapy
Exhibit 63 Healthcare Expenditure of Western European Countries Relative to their GDP
Exhibit 64 Cell & Gene Therapy Market in Western Europe: Incremental Growth & Absolute Growth Comparison
Exhibit 65 Cell & Gene Therapy Market in Western Europe 2020–2026 ($ million)
Exhibit 66 Healthcare Expenditure of Eastern European Countries Relative to their GDP
Exhibit 67 Cell & Gene Therapy Market in Rest of Europe: Incremental Growth & Absolute Growth Comparison
Exhibit 68 Cell & Gene Therapy Market in Rest of Europe 2020–2026 ($ million)
Exhibit 69 Incremental Growth in Key Countries 2020 & 2026
Exhibit 70 Cell and Gene Therapy Market in Germany 2020–2026 ($ million)
Exhibit 71 Cell and Gene Therapy Market in France 2020–2026 ($ million)
Exhibit 72 Cell and Gene Therapy Market in UK 2020–2026 ($ million)
Exhibit 73 Cell and Gene Therapy Market in Italy 2020–2026 ($ million)
Exhibit 74 Cell and Gene Therapy Market in Spain 2020–2026 ($ million)
Exhibit 75 Cell and Gene Therapy Market in Switzerland 2020–2026 ($ million)
Exhibit 76 Cell and Gene Therapy Market in Netherlands 2020–2026 ($ million)
Exhibit 77 Novartis Revenue 2017-2019 ($ billion)
Exhibit 78 Novartis Segment Revenue Share 2019
Exhibit 79 Novartis: Regional Revenue Breakup 2019 (%)
Exhibit 80 Amgen Revenue 2019 - 2017 ($ billion)
Exhibit 81 Amgen: R&D Expenditure 2019 - 2017 ($ billion)
Exhibit 82 Gilead Sciences Revenue 2017–2019 ($ billion)
Exhibit 83 Gilead Sciences Research &Development Expenses 2017–2019 ($ billion)
Exhibit 84 Organogenesis Revenue 2018–2019 ($ million)
LIST OF TABLES
Table 1 Key Caveats
Table 2 Currency Conversion 2013?2020
Table 3 Comparison of Conventional Therapy Versus ATMPs
Table 4 CMO Vector Manufacturers in Europe
Table 5 Gene Therapies in Significant Stages of Clinical Pipeline
Table 6 Recent Strategic Acquisitions in Europe Cell & Gene Therapy Market
Table 7 Product Approvals & Launches
Table 8 Major Cell & Gene Therapy Products Anticipated Near-Term Approvals in Europe
Table 9 Major Cell & Gene Therapy Products Anticipated Near-Term Approvals in Europe
Table 10 Major Cell & Gene Therapy Products Approved in Europe
Table 11 Gene Therapy Product Approved BY EMA
Table 12 Oncology Application Based Cell & Gene Therapy Products
Table 13 Oncology Application Based Cell & Gene Therapy Products
Table 14 Oncology Application Based Cell & Gene Therapy Products
Table 15 Other Application Based Cell & Gene Therapy Products
Table 16 Novartis: Major Product Offerings
Table 17 Spark Therapeutics: Major Product Offerings
Table 18 Amgen: Major Product Offerings
Table 19 Gilead Sciences: Major Product Offerings
Table 20 Organogenesis: Major Product Offerings
Table 21 APAC Biotech: Major Product Offerings
Table 22 AVITA MEDICAL: Major Product Offerings
Table 23 bluebird bio: Major Product Offerings
Table 24 CHIESI Farmaceutici: Major Product Offerings
Table 25 COLLPLANT: Major Product Offerings
Table 26 CO.DON: Major Product Offerings
Table 27 Human Stem Cell Institute: Major Product Offerings
Table 28 MEDIPOST: Major Product Offerings
Table 29 NUVASIVE: Major Product Offerings
Table 30 NIPRO: Major Product Offerings
Table 31 Orchard Therapeutics: Major Product Offerings
Table 32 RMS Regenerative Medical System: Major Product Offerings
Table 33 Orthocell: Major Product Offerings
Table 34 Osiris Therapeutics: Major Product Offerings
Table 35 Sibino GeneTech: Major Product Offerings
Table 36 Shanghai Sunway Biotech: Major Product Offerings
Table 37 Takeda Pharmaceutical Company: Major Product Offerings
Table 38 Terumo: Major Product Offerings
Table 39 Vericel: Major Product Offerings
Table 40 Cell & Gene Therapy Market by Geography 2020?2026 ($ million)
Table 41 Cell& Gene Therapy Market by Geography 2020?2026 (%)
Table 42 Cell & Gene Therapy Market by Product 2020?2026 ($ million)
Table 43 Cell& Gene Therapy Market by Product 2020?2026 (%)
Table 44 Cell & Gene Therapy Market by End-User 2020?2026 ($ million)
Table 45 Cell& Gene Therapy Market by End-User 2020?2026 (%)
Table 46 Cell & Gene Therapy Market by Application 2020?2026 ($ million)
Table 47 Cell& Gene Therapy Market by Application 2020?2026 (%)
Table 1 Key Caveats
Table 2 Currency Conversion 2013?2020
Table 3 Comparison of Conventional Therapy Versus ATMPs
Table 4 CMO Vector Manufacturers in Europe
Table 5 Gene Therapies in Significant Stages of Clinical Pipeline
Table 6 Recent Strategic Acquisitions in Europe Cell & Gene Therapy Market
Table 7 Product Approvals & Launches
Table 8 Major Cell & Gene Therapy Products Anticipated Near-Term Approvals in Europe
Table 9 Major Cell & Gene Therapy Products Anticipated Near-Term Approvals in Europe
Table 10 Major Cell & Gene Therapy Products Approved in Europe
Table 11 Gene Therapy Product Approved BY EMA
Table 12 Oncology Application Based Cell & Gene Therapy Products
Table 13 Oncology Application Based Cell & Gene Therapy Products
Table 14 Oncology Application Based Cell & Gene Therapy Products
Table 15 Other Application Based Cell & Gene Therapy Products
Table 16 Novartis: Major Product Offerings
Table 17 Spark Therapeutics: Major Product Offerings
Table 18 Amgen: Major Product Offerings
Table 19 Gilead Sciences: Major Product Offerings
Table 20 Organogenesis: Major Product Offerings
Table 21 APAC Biotech: Major Product Offerings
Table 22 AVITA MEDICAL: Major Product Offerings
Table 23 bluebird bio: Major Product Offerings
Table 24 CHIESI Farmaceutici: Major Product Offerings
Table 25 COLLPLANT: Major Product Offerings
Table 26 CO.DON: Major Product Offerings
Table 27 Human Stem Cell Institute: Major Product Offerings
Table 28 MEDIPOST: Major Product Offerings
Table 29 NUVASIVE: Major Product Offerings
Table 30 NIPRO: Major Product Offerings
Table 31 Orchard Therapeutics: Major Product Offerings
Table 32 RMS Regenerative Medical System: Major Product Offerings
Table 33 Orthocell: Major Product Offerings
Table 34 Osiris Therapeutics: Major Product Offerings
Table 35 Sibino GeneTech: Major Product Offerings
Table 36 Shanghai Sunway Biotech: Major Product Offerings
Table 37 Takeda Pharmaceutical Company: Major Product Offerings
Table 38 Terumo: Major Product Offerings
Table 39 Vericel: Major Product Offerings
Table 40 Cell & Gene Therapy Market by Geography 2020?2026 ($ million)
Table 41 Cell& Gene Therapy Market by Geography 2020?2026 (%)
Table 42 Cell & Gene Therapy Market by Product 2020?2026 ($ million)
Table 43 Cell& Gene Therapy Market by Product 2020?2026 (%)
Table 44 Cell & Gene Therapy Market by End-User 2020?2026 ($ million)
Table 45 Cell& Gene Therapy Market by End-User 2020?2026 (%)
Table 46 Cell & Gene Therapy Market by Application 2020?2026 ($ million)
Table 47 Cell& Gene Therapy Market by Application 2020?2026 (%)
